Anderson Kenneth Carl - Insider Non-Derivative Transactions at C4 Therapeutics, Inc. (CCCC) - (SEC)

Updated on January 3, 2026.

According to recent SEC insider information filed on Oct 1, 2025, Anderson Kenneth Carl's relationship to C4 Therapeutics, Inc. (CCCC) is Director, and currently has 140,574 shares of Common Stock.

The chart below shows the number of shares owned, and the table shows the recent insider transactions.

You can see similar information for other CCCC insiders.

Related Topics: SEC Topic List.

Data Source: SEC.

Anderson Kenneth Carl - Insider Non-Derivative Transactions of CCCC Common Stock

Anderson Kenneth Carl - Insider Non-Derivative Transactions at CCCC

Items per page:

0 of 0

Date	Transaction	No. of Shares	Price Per Share	Shares Owned After Transactions
Oct 2, 2025	Acquisition -- (Common Stock)	5349	2.15	140574
Jul 2, 2025	Acquisition -- (Common Stock)	7616	1.51	135225
Apr 2, 2025	Acquisition -- (Common Stock)	7841	1.44	127609
Jan 3, 2025	Acquisition -- (Common Stock)	3074	3.66	119768
Oct 2, 2024	Acquisition -- (Common Stock)	2023	5.56	116694
Jul 2, 2024	Acquisition -- (Common Stock)	2320	4.85	114671
Apr 2, 2024	Acquisition -- (Common Stock)	1389	8.1	112351
Jan 3, 2024	Acquisition -- (Common Stock)	1725	6.52	110962
Oct 3, 2023	Acquisition -- (Common Stock)	6617	1.7	109237
Jul 4, 2023	Acquisition -- (Common Stock)	3976	2.83	102620
Apr 4, 2023	Acquisition -- (Common Stock)	3516	3.2	98644
Jan 7, 2023	M -- (Common Stock)	268	2.11	94684
Jan 7, 2023	M -- (Common Stock)	444	4.98	95128
Jan 4, 2023	Acquisition -- (Common Stock)	1568	6.38	94416